GSK3B and Alzheimer disease: As shown in Fig. 8d, GSK3B, APP, and MAPT induce two clinical phenotypes in AD pathology, neuronal loss, and neurodegeneration, by affecting four molecular-level physiological processes, including the apoptotic process, inflammatory response, synaptic transmission, and neuron projection development.